SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Q36811227)
Jump to navigation
Jump to search
scientific article published on 29 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen |
scientific article published on 29 January 2013 |
Statements
1 reference
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (English)
1 reference
R Campo
1 reference
E DeJesus
1 reference
U F Bredeek
1 reference
K Henry
1 reference
H Khanlou
1 reference
K Logue
1 reference
C Brinson
1 reference
P Benson
1 reference
L Dau
1 reference
H Wang
1 reference
K White
1 reference
J Flaherty
1 reference
T Fralich
1 reference
B Guyer
1 reference
D Piontkowsky
1 reference
1 reference
Identifiers
1 reference